Drug
VS 7375
VS 7375: highest development phase Phase 2, developed by Verastem, Inc.. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Verastem, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| VS-7375 NCT07644559 | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) |
| VS-7375 NCT07659782 | Phase 2 | Non-Small Cell Lung Cancer |
Latest
No recent events.
Follow VS 7375 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.